For more than 50 years, biopharmaceutical companies have partnered with the Food and Drug Administration (FDA) to help ensure the safety and efficacy of medicines.
If you’re like me, physical education class was a welcome break from history and math. Unfortunately, it is being cut from school programs.
Bob Hugin, Chairman and CEO, Celgene and Chairman of the PhRMA Board, recently sat down with Life Science Leader magazine to talk about the value of medical innovation. If you haven’t read it already, I urge you to do so because Bob offers some very insightful thoughts on why we
With TPP, Indian and other IP infringement and innovation issues shaping international headlines in recent weeks, IP is increasingly being recognized as a central driver of growth, development and access to medicines.
PhRMA’s Rick Smith, Executive Vice President of Policy and Research, testified today in a hearing called, “10 Years Later: A Look at the Medicare Prescription Drug Program,” hosted by the Senate’s Special Committee on Aging.
With the 17th round of Trans-Pacific Partnership negotiations taking place in Lima, Peru, the importance of strong U.S. trade and innovation policy is once again front and center.
In Colombia, unprecedented price controls in the private market are being contemplated and such policies – a threat to continued research and development of new medicines – are already in effect in El Salvador and also under consideration elsewhere in the region.
This past weekend the American Journal of Managed Care released a study titled, “The Economic Impact of Medicare Part D on Congestive Heart Failure.”
Uplifting Athletes is a nonprofit organization that works with college football players to raise awareness of rare disease, raise funds for research and support individual rare disease patients. The chapters are run by student athletes at universities across the country. Their work recently gained national attention when the
Recently, I had the pleasure of sitting down with Olof Larsson, chief scientific officer, Eli Lilly and Company, to talk about what inspired him to get into science and what advice he has for students as they explore their future career path. I met Olof, originally from Sweden, at his house in Indianapolis, IN and as I walked through the front door, he introduced me to his daughter who is current
It’s always tough reading biased coverage, especially when reporters continue to slam collaboration between physicians and biopharmaceutical companies. I was particularly taken aback by Roni Caryn Rabin’s treatment of the issue in New York Times’ Well blog this week.
A recent article in Scientific American which explains “Why Doctors Prescribe Off-Label Drugs” caught my attention since non-approved use, also known as off-label use, of prescription medicines is often mentioned in the news without the context of why doctors choose to recommend it.
Can women really “have it all?” It is an age-old question that continues to generate significant societal interest and discussion.
Following our focus on young innovators this week, I’m reminded that ongoing research and innovation significantly improves the lives of patients and contributes to the health of our economy. The pace of innovation is staggering, and with so much information available at our fingertips, ensuring patients are utilizing reliable, accurate sources to make the best decisions for their health can be a challenge.
Nobody better represents the exciting science of our sector than those who are rolling up their sleeves and engaging in innovative biopharmaceutical research every day. As a result, we at PhRMA and our member companies are excited to highlight the stories and lives of some of our inspiring scientists. These individuals epitomize the passion, diversity, excitement, commitment and intellectual prowess of biopharmaceutical scientists. And they set an example for future generations of promising biopharma researchers.
Hurricane season is coming. It starts in less than a month. Now’s the time to get prepared. Here’s a clip from the Barometer Bob Show on the Weather Radio Broadcast Network. In this edition, Barometer Bob interviews RxResponse Executive Director Erin Mullen.
IMS’ latest report, Declining Medicine Use and Costs: For Better or Worse, reasserts the value that medicines provide in improving patients’ health and saving money on future health care costs. It’s also a great example of how and why the life cycle of medicines works so well.